-
1
-
-
0023689451
-
Distant metastases in differentiated thyroid carcinoma: A multivariate analysis of prognostic variables
-
Ru egemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67:501-50 8.
-
(1988)
J Clin Endocrinol Metab
, vol.67
, pp. 501-508
-
-
Ru Egemer, J.J.1
Hay, I.D.2
Bergstralh, E.J.3
Ryan, J.J.4
Offord, K.P.5
Gorman, C.A.6
-
2
-
-
0042166011
-
Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma
-
Shoup M, Stojadinovic A, Nissan A, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003;197:191-197.
-
(2003)
J Am Coll Surg
, vol.197
, pp. 191-197
-
-
Shoup, M.1
Stojadinovic, A.2
Nissan, A.3
-
3
-
-
33747642244
-
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy
-
Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 2892-2899
-
-
Durante, C.1
Haddy, N.2
Baudin, E.3
-
5
-
-
84875305916
-
Optimizing therapy for radioactive iodinerefractory differentiated thyroid cancer: Current state of the art and future directions
-
Dadu R, Cabanillas ME. Optimizing therapy for radioactive iodinerefractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol. 2012;37:335-356.
-
(2012)
Minerva Endocrinol
, vol.37
, pp. 335-356
-
-
Dadu, R.1
Cabanillas, M.E.2
-
6
-
-
63849265332
-
Phase II trial of sorafenib in metastatic thyroid cancer
-
Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-1684.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1675-1684
-
-
Kloos, R.T.1
Ringel, M.D.2
Knopp, M.V.3
-
7
-
-
50649095250
-
Phase II trial of sorafenib in advanced thyroid cancer
-
Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-4719.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4714-4719
-
-
Gupta-Abramson, V.1
Troxel, A.B.2
Nellore, A.3
-
8
-
-
72949106263
-
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differe ntiated thyroid carcinoma
-
Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differe ntiated thyroid carcinoma. Eur J Endocrinol. 2009;161:923-931.
-
(2009)
Eur J Endocrinol
, vol.161
, pp. 923-931
-
-
Hoftijzer, H.1
Heemstra, K.A.2
Morreau, H.3
-
9
-
-
84867527699
-
Long term analysis of the efficacy and tolerabi lity of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: Final results of a phase II trial
-
Schneider T, Abdulrahman R, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long term analysis of the efficacy and tolerabi lity of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012; 167:643-650.
-
(2012)
Eur J Endocrinol
, vol.167
, pp. 643-650
-
-
Schneider, T.1
Abdulrahman, R.2
Corssmit, E.P.3
Morreau, H.4
Smit, J.W.5
Kapiteijn, E.6
-
10
-
-
79960179069
-
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population
-
Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011;165:315-322.
-
(2011)
Eur J Endocrinol
, vol.165
, pp. 315-322
-
-
Ahmed, M.1
Barbachano, Y.2
Riddell, A.3
-
11
-
-
84887111477
-
Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial
-
abstract 4
-
Brose M, Nuyying C, Jarzab B, et al . Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol. 2013;31:abstract 4.
-
(2013)
J Clin Oncol
, vol.31
-
-
Brose, M.1
Nuyying, C.2
Jarzab, B.3
-
12
-
-
62849099971
-
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib
-
Zimmermann K, Schm ittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology. 2009;76:350-354.
-
(2009)
Oncology
, vol.76
, pp. 350-354
-
-
Zimmermann, K.1
Schm Ittel, A.2
Steiner, U.3
-
13
-
-
58949092548
-
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
-
Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61-67.
-
(2009)
Cancer
, vol.115
, pp. 61-67
-
-
Dudek, A.Z.1
Zolnierek, J.2
Dham, A.3
Lindgren, B.R.4
Szczylik, C.5
-
14
-
-
79959782949
-
Sequenti al use of sorafenib and sunitinib in advanced renal-cell carcinoma (rcc): An Italian multicentre retrospective analysis of 189 patient cases
-
Porta C, Procopio G, Carteni G, et al. Sequenti al use of sorafenib and sunitinib in advanced renal-cell carcinoma (rcc): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011; 108:E250-E257.
-
(2011)
BJU Int
, vol.108
-
-
Porta, C.1
Procopio, G.2
Carteni, G.3
-
15
-
-
84858710583
-
Targeted therapies used sequentially in metastatic renal cell cancer: Overall results from a large experience
-
Procopio G, Verzoni E, Iaco velli R, Guadalupi V, Gelsomino F, Buzzoni R. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther. 2011;11:1631-1640.
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, pp. 1631-1640
-
-
Procopio, G.1
Verzoni, E.2
Iaco Velli, R.3
Guadalupi, V.4
Gelsomino, F.5
Buzzoni, R.6
-
16
-
-
67349163859
-
Sequential sorafenib and sunitinib for renal cell carcinoma
-
Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29-34.
-
(2009)
J Urol
, vol.182
, pp. 29-34
-
-
Sablin, M.P.1
Negrier, S.2
Ravaud, A.3
-
17
-
-
84875151746
-
Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC
-
abstract 5547
-
Cabanillas ME, Brose M, Lee Y, Mile s D, Sherman SI. Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). J Clin Oncol Vol. 2012;30: abstract 5547.
-
J Clin Oncol
, vol.2012
, pp. 30
-
-
Cabanillas, M.E.1
Brose, M.2
Lee, Y.3
Mile, S.D.4
Sherman, S.I.5
-
18
-
-
78049462514
-
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation
-
Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010; 16:5260-5268.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5260-5268
-
-
Carr, L.L.1
Mankoff, D.A.2
Goulart, B.H.3
-
19
-
-
77954476036
-
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience
-
Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin End ocrinol Metab. 2010;95:2588-2595.
-
(2010)
J Clin End Ocrinol Metab
, vol.95
, pp. 2588-2595
-
-
Cabanillas, M.E.1
Waguespack, S.G.2
Bronstein, Y.3
-
20
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
21
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1
-
Eisenhauer EA Therasse P Bogaerts J et al New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1 Eur J Cancer. 2009 45 228-247.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
22
-
-
77957359933
-
Efficacy of pazopanib in progressive, radioio dine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study
-
Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioio dine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11:962-972.
-
(2010)
Lancet Oncol
, vol.11
, pp. 962-972
-
-
Bible, K.C.1
Suman, V.J.2
Molina, J.R.3
-
23
-
-
84865552505
-
Vandetanib in loc ally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial
-
Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in loc ally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897-905.
-
(2012)
Lancet Oncol
, vol.13
, pp. 897-905
-
-
Leboulleux, S.1
Bastholt, L.2
Krause, T.3
-
24
-
-
80053160399
-
A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC
-
Abstract 5503
-
Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011; 29:Abstract 5503.
-
(2011)
J Clin Oncol
, vol.29
-
-
Sherman, S.I.1
Jarzab, B.2
Cabanillas, M.E.3
|